LXRX Stock Overview
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products.
Lexicon Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.03|
|52 Week High||US$6.33|
|52 Week Low||US$1.31|
|1 Month Change||20.83%|
|3 Month Change||-2.87%|
|1 Year Change||-64.51%|
|3 Year Change||-67.73%|
|5 Year Change||-87.66%|
|Change since IPO||-98.45%|
Recent News & Updates
Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Lexicon: Beaten Down Stock, High Risk-Reward Situation Ahead
Lexicon has not been lucky with the FDA. However, there are reasons, discussed below, which make me see a special situation here. It may not be a bad idea to take the plunge.
|LXRX||US Biotechs||US Market|
Return vs Industry: LXRX underperformed the US Biotechs industry which returned -24.4% over the past year.
Return vs Market: LXRX underperformed the US Market which returned -18.5% over the past year.
|LXRX Average Weekly Movement||12.4%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: LXRX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: LXRX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals Fundamentals Summary
|LXRX fundamental statistics|
Is LXRX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LXRX income statement (TTM)|
|Cost of Revenue||US$57.36m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.60|
|Net Profit Margin||-29,310.39%|
How did LXRX perform over the long term?See historical performance and comparison
Is LXRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LXRX?
Other financial metrics that can be useful for relative valuation.
|What is LXRX's n/a Ratio?|
Price to Book Ratio vs Peers
How does LXRX's PB Ratio compare to its peers?
|LXRX PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
Price-To-Book vs Peers: LXRX is expensive based on its Price-To-Book Ratio (3.3x) compared to the peer average (1.5x).
Price to Earnings Ratio vs Industry
How does LXRX's PE Ratio compare vs other companies in the U.S. Biotechs Industry?
Price-To-Book vs Industry: LXRX is expensive based on its Price-To-Book Ratio (3.3x) compared to the US Biotechs industry average (1.6x)
Price to Book Ratio vs Fair Ratio
What is LXRX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||3.3x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate LXRX's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of LXRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate LXRX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate LXRX's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LXRX's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Lexicon Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LXRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LXRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LXRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LXRX's revenue (117.5% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: LXRX's revenue (117.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LXRX is forecast to be unprofitable in 3 years.
Discover growth companies
How has Lexicon Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LXRX is currently unprofitable.
Growing Profit Margin: LXRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LXRX is unprofitable, but has reduced losses over the past 5 years at a rate of 25% per year.
Accelerating Growth: Unable to compare LXRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LXRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: LXRX has a negative Return on Equity (-97.39%), as it is currently unprofitable.
Discover strong past performing companies
How is Lexicon Pharmaceuticals's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: LXRX's short term assets ($88.4M) exceed its short term liabilities ($18.9M).
Long Term Liabilities: LXRX's short term assets ($88.4M) exceed its long term liabilities ($24.6M).
Debt to Equity History and Analysis
Debt Level: LXRX has more cash than its total debt.
Reducing Debt: LXRX's debt to equity ratio has reduced from 75.2% to 25.3% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LXRX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: LXRX has less than a year of cash runway if free cash flow continues to grow at historical rates of 6.4% each year.
Discover healthy companies
What is Lexicon Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LXRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LXRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LXRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LXRX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as LXRX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Lonnel Coats (56 yo)
Mr. Lonnel Coats has been the Chief Executive Officer of Lexicon Pharmaceuticals, Inc., since July 7, 2014. He was President of Lexicon Pharmaceuticals, Inc since July 7, 2014 until October 01, 2021. Mr. C...
CEO Compensation Analysis
Compensation vs Market: Lonnel's total compensation ($USD3.92M) is above average for companies of similar size in the US market ($USD2.84M).
Compensation vs Earnings: Lonnel's compensation has increased whilst the company is unprofitable.
Experienced Management: LXRX's management team is seasoned and experienced (7.9 years average tenure).
Experienced Board: LXRX's board of directors are seasoned and experienced ( 14.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.6%.
Lexicon Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Lexicon Pharmaceuticals, Inc.
- Ticker: LXRX
- Exchange: NasdaqGS
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$303.675m
- Shares outstanding: 149.59m
- Website: https://www.lexpharma.com
Number of Employees
- Lexicon Pharmaceuticals, Inc.
- 2445 Technology Forest Boulevard
- 11th Floor
- The Woodlands
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.